Entrada TherapeuticsvsUnitedHealth

TRDA and UNH stock compared: price, dividend, valuation and results, from SEC filings.

TRDA

Entrada Therapeutics, Inc.

$4.96

Value $190M

-0.80%
TRDA's page

UNH

UnitedHealth Group Incorporated

$389.68

Value $354B

-5.42%
UNH's page

Entrada Therapeutics (TRDA) has a market value of $190M and UnitedHealth (UNH) $354B. Over the last year, with dividends, TRDA moved -43.3% and UNH +24.3%. Dividend yield: TRDA none, UNH 2.32%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    TRDA$190M

    UNH$354B

    UNH is 1,863 times TRDA

  • Revenue, 12 months

    TRDA$4.0M

    UNH$450B

    UNH is 113,066 times TRDA

  • Net income, 12 months

    TRDA-$161M

    UNH$15.9B

  • Operating margin

    TRDA-4,303.8%

    UNH5.3%

    4,309.1 points apart

  • ROIC

    TRDA-50.1%

    UNH11.3%

    61.4 points apart

  • P/E

    TRDA–

    UNH22.3

  • Dividend yield

    TRDA0.0%

    UNH2.3%

    2.3 points apart

  • 5-year return

    TRDA-85.5%

    UNH-5.1%

    80.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

TRDA-85.5%

UNH-5.1%

5010020222023202420252026
Returns by period
PeriodTRDAWith dividendsUNHWith dividends
1 year since November 14, 2025-43.3%Price -43.3%+24.3%Price +21.1%
3 years since November 17, 2023-69.4%-32.6% a yearPrice -69.4%-22.6%-8.2% a yearPrice -27.3%
5 years since November 16, 2021-85.5%-32.0% a yearPrice -85.5%-5.1%-1.0% a yearPrice -13.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

TRDAEntrada TherapeuticsUNHUnitedHealth

Valuation

TRDAUNH
Valuation
Price$4.96$389.68
Market value$190M$354B
Enterprise value (EV)–$399B
P/E–22.3
P/E, 5-year median–25.0
P/B1.03.4
EV/EBIT–16.7
Free cash flow yield–6.5%

Results and growth

TRDAUNH
Results and growth
Revenue, 12 months$4.0M$450B
Net income, 12 months-$161M$15.9B
Free cash flow, 12 months-$136M$22.8B
Earnings per share, 12 months-$3.84$17.52
Revenue growth, year on year-87.9%11.8%
Revenue growth a year, past-55.6%over 2 years+11.7%over 5 years
EPS growth a year, past–-3.8%over 5 years

Margins and returns on capital

TRDAUNH
Margins and returns on capital
Gross margin–88.3%
Operating margin-4,303.8%5.3%
Net margin-4,058.0%3.5%
ROIC-50.1%11.3%
ROE-59.8%15.5%

Balance sheet

TRDAUNH
Balance sheet
Cash$193M$28.5B
Total debt$47M$74.3B
Net debt / EBITDA–1.6
Interest cover–6.2×

Dividends and buybacks

TRDAUNH
Dividends and buybacks
Dividend yield–2.3%
Dividend per share, 12 months–$9.06
Dividend growth a year, past–+12.6%over 5 years
Buyback yield–1.6%
Shareholder yield–3.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: TRDA or UNH

Didn't find what you were looking for?

Ask us
Which is bigger, Entrada Therapeutics or UnitedHealth?

By market value, UnitedHealth ($354B) is about 1,862.7 times Entrada Therapeutics ($190M), at today's prices.

How did TRDA and UNH stock do over the last 5 years?

Since November 16, 2021, TRDA's price moved -85.5% and UNH's -13.3%. With dividends: TRDA -85.5% (-32.0% a year), UNH -5.1% (-1.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, TRDA or UNH?

The dividend yield at today's price is none for Entrada Therapeutics and 2.32% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.

Which has the higher profit margins, Entrada Therapeutics or UnitedHealth?

Over the last twelve months, the net margin was -4,058.0% for Entrada Therapeutics and 3.5% for UnitedHealth, and the operating margin -4,303.8% and 5.3%. Revenue was $4.0M and $450B.

Which is the better investment, Entrada Therapeutics or UnitedHealth?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.